Molecular Response, LLC is a Biotech Investment Group (B.I.G.) Company: www.bioinv.com
Masood Tayebi, Ph.D.
Dr. Tayebi is currently the chairman of Biotech Investment Group (B.I.G.), a San Diego private equity firm, with key investments in protein therapeutics and molecular diagnostics. Dr. Tayebi brings the wealth of experience and critical insights into the service sector, gained through his success in the telecom industry, and in founding BioDuro, a preclinical CRO he successfully guided to acquisition by Pharmaceutical Product Development, Inc. in November 2009. Dr. Tayebi has been involved in founding, financing, and managing numerous companies. He founded, built, and managed WFI, the leading global services firm to the wireless industry, with over 2,700 employees and operations in over 60 countries. In 2000, WFI had a market capitalization of over $7 billion. Dr. Tayebi is a direct investor with sizable holdings in 9 venture firms including Oak Investment Partners and Credit Suisse’s venture fund. Prior to co-founding WFI, Dr. Tayebi enjoyed a successful engineering career with several multinational corporations including British Telecom and LCC International. Dr. Tayebi received his PhD in mobile radio propagation from the University of Liverpool, and his M.S. in electronics engineering from the University of Southampton.
Brett Hall, Ph.D.
Chief Executive Officer (CEO)
Dr. Hall is a U.S. Air Force veteran and former investment banker (Series 6 and 63). He obtained his B.S. from the Ohio State University (Biochemistry) and Ph.D. from West Virginia University, studying how the tumor microenvironment affects tumor growth, metastasis and survival. He did his post-doctoral work at St. Jude Children’s Hospital (Memphis, TN, USA) and Nationwide Children’s Hospital (NCH; Columbus, OH, USA) before accepting a tenure track faculty position at the Ohio State University, Department of Pediatrics. Dr. Hall’s laboratory focused on tumor-stromal cell modeling in physiologically relevant human tumor microenvironments. He also led the design, development and operation of a multi-million dollar small animal imaging core facility at Nationwide Children’s Hospital. He transitioned to Janssen, LLC. (pharmaceutical division of J&J) where he led the European translational medicine group and patient-derived xenograft (PDX) biomarker efforts in Beerse, Belgium. Dr. Hall transitioned to the U.S. to lead the J&J Hematologic Oncology Disease Area Stronghold (Heme-DAS) translational group. In this new role, he oversaw the translational efforts of 8 clinical assets and registered two oncology drugs (siltuximab; an anti-IL-6 mAb and ibrutinib; a small molecule BTK inhibitor). A third drug, Daratumumab, recently received accelerated approval by the FDA (c.2015). In 2014, Dr. Hall transitioned to MedImmune, the biologics division of AstraZeneca, where he led the Oncology Translational Medicine group and over 15 clinical programs. Dr. Hall has over 35 scientific publications, a patent for ibrutinib clinical combinations and has been recognized for direct translational support and contributing to successful acquisition/partnering of multiple oncology drugs including ibrutinib (BTK inhibitor for multiple heme indications) and Daratumumab (anti-CD38 mAb for multiple myeloma).
Praveen Nair, Ph.D.
Senior Director (Scientific & Biobanking Operations)
Dr. Nair received his B.S. from Kerala Agricultural University in India (with a focus in Developmental and Comparative Immunology) and Ph.D. in Medical Microbiology from the University of Georgia (Athens, GA, USA). After his Ph.D., he spent three years at University of Chicago’s Pritzker School of Medicine, investigating molecular mechanisms responsible for immune dysfunction within tumor microenvironment. Dr. Nair joined Molecular Response in 2010 and lead efforts in establishment and characterization of various platforms for improving personalized treatment strategies across multiple cancer indications. As the Head of Operations, he played a significant role in setting up a large repository of patient-derived tumor tissue and developing novel strategies to test various drug candidates in physiologically relevant models that mimic the tumor microenvironment. Praveen provided leadership and expertise in evaluating novel technologies as tools for drug development programs. Dr. Nair has over 14 scientific publications and has been awarded various honors including Robert C Anderson memorial award for excellence in research by the University of Georgia.